Fowl Pox and Mycoplasma Gallisepticum Vaccine Considerations in Poultry
Introduction
Respiratory and proliferative diseases in poultry represent a significant economic burden on commercial flocks worldwide. Two pathogens of particular importance are fowl pox virus (FPV), a DNA virus of the genus Avipoxvirus, and Mycoplasma gallisepticum (MG), a cell wall deficient bacterium of the class Mollicutes. Both agents cause chronic, production-limiting diseases that often require vaccination as a cornerstone of control programs. This article provides a detailed technical review of vaccine considerations for these two pathogens, including vaccine types, administration routes, efficacy parameters, and differential diagnostic challenges.
Fowl Pox: Etiology and Pathogenesis
Fowl pox is caused by fowl pox virus, a large double-stranded DNA virus belonging to the family Poxviridae, subfamily Chordopoxvirinae, genus Avipoxvirus. The virus replicates in the cytoplasm of epithelial cells and produces characteristic intracytoplasmic inclusion bodies (Bollinger bodies). Transmission occurs via mechanical vectors (mosquitoes, biting flies), direct contact, or contaminated fomites. The disease manifests in two forms: the cutaneous (dry) form, characterized by proliferative lesions on unfeathered skin (comb, wattles, legs), and the diphtheritic (wet) form, with fibronecrotic lesions in the upper respiratory and digestive mucosa. The diphtheritic form carries higher mortality due to respiratory obstruction.
Mycoplasma Gallisepticum: Etiology and Pathogenesis
Mycoplasma gallisepticum is a small (0.2 to 0.3 micrometer), pleomorphic, facultatively anaerobic bacterium that lacks a cell wall. This structural absence renders it resistant to beta-lactam antibiotics and necessitates specialized culture media supplemented with sterols. MG colonizes the respiratory epithelium of chickens and turkeys, causing chronic respiratory disease (CRD). The organism adheres to ciliated epithelial cells via cytadhesin proteins (GapA, CrmA) and induces ciliostasis, inflammation, and secondary bacterial infections. MG is transmitted vertically (transovarian) and horizontally via aerosols and fomites. Co-infection with respiratory viruses (e.g., infectious bronchitis virus, Newcastle disease virus) or bacteria (e.g., Escherichia coli, see Escherichia coli in Chickens and Poultry Products) exacerbates clinical severity.
Vaccine Types for Fowl Pox
Live Attenuated Vaccines
The most widely used fowl pox vaccines are live attenuated viruses propagated in embryonated chicken eggs or cell culture. Attenuation is achieved through serial passage in heterologous hosts or cell lines, resulting in reduced virulence while retaining immunogenicity. Two main types exist:
- Fowl Pox Virus (FPV) Vaccines: Derived from the original fowl pox virus strain, these vaccines protect against fowl pox specifically.
- Pigeon Pox Virus (PPV) Vaccines: These are heterologous vaccines that provide cross-protection against fowl pox. PPV vaccines are often considered milder and are used in younger birds or in flocks with low challenge pressure.
Recombinant Vaccines
Recombinant fowl pox vaccines have been developed using fowl pox virus as a vector for expressing immunogenic proteins from other avian pathogens (e.g., Newcastle disease virus, avian influenza virus). These vectored vaccines offer the advantage of dual protection but are not primarily indicated for fowl pox control alone. They are administered in ovo or subcutaneously.
Inactivated Vaccines
Inactivated (killed) fowl pox vaccines are not commercially common due to the strong cell-mediated immune response required for protection against poxviruses. Inactivated vaccines typically induce a weaker cytotoxic T lymphocyte (CTL) response compared to live vaccines. They are occasionally used in breeder flocks as a booster following live priming.
Vaccine Types for Mycoplasma Gallisepticum
Live Attenuated Vaccines
Live MG vaccines are derived from naturally occurring or artificially attenuated strains. The most commonly used strains include:
- F strain: Moderately virulent, administered via eye drop or spray. It colonizes the respiratory tract and provides good protection against field challenge. However, it retains some residual virulence and can cause disease in turkeys.
- ts-11 strain: A temperature-sensitive mutant that replicates at lower temperatures (33 degrees Celsius) but is restricted at body temperature (41 degrees Celsius). It is administered via eye drop and is considered safer than the F strain, with minimal shedding.
- 6/85 strain: An apathogenic strain administered via coarse spray. It provides moderate protection and is used primarily in layer flocks.
Live MG vaccines induce mucosal IgA and systemic IgG responses, as well as cell-mediated immunity. They are contraindicated in flocks with concurrent immunosuppressive diseases (e.g., infectious bursal disease, chicken anemia virus).
Inactivated (Bacterin) Vaccines
Inactivated MG vaccines are oil-adjuvanted bacterins administered intramuscularly or subcutaneously. They induce a strong humoral IgG response but limited mucosal immunity. Bacterins are used primarily in breeder flocks to reduce egg transmission and protect progeny via maternal antibodies. They do not prevent colonization but reduce clinical signs and egg production losses.
Administration Routes
Fowl Pox Vaccines
- Wing Web Stab: The standard route for live fowl pox vaccines. A double-needle applicator is dipped into the vaccine and used to puncture the wing web. A visible "take" (swelling and scab formation at the inoculation site) develops 5 to 10 days post-vaccination, indicating successful immunization. Lack of a take suggests vaccine failure, improper administration, or prior immunity.
- Subcutaneous Injection: Used for recombinant fowl pox vectored vaccines in day-old chicks.
- In Ovo Vaccination: Used for some recombinant vaccines in commercial broiler hatcheries.
Mycoplasma Gallisepticum Vaccines
- Eye Drop: The preferred route for live MG vaccines (ts-11, F strain). A drop is placed onto the conjunctiva, allowing direct contact with the Harderian gland and respiratory mucosa. This route ensures optimal mucosal immunity.
- Coarse Spray: Used for the 6/85 strain. A coarse droplet size (100 to 200 micrometers) is used to minimize deep lung penetration and vaccine reaction.
- Intramuscular or Subcutaneous Injection: Used for inactivated MG bacterins. The injection site is typically the breast or leg muscle.
Efficacy Considerations
Fowl Pox Vaccine Efficacy
Efficacy of fowl pox vaccines is assessed by the development of a vaccine "take" and by challenge studies. Protection correlates with the induction of virus-neutralizing antibodies and CTL responses. Factors reducing efficacy include:
- Improper vaccine storage or reconstitution.
- Administration to birds with maternal antibodies (for live vaccines).
- Concurrent immunosuppression.
- Mismatch between vaccine strain and field strain (rare for fowl pox, as cross-protection is broad).
Mycoplasma Gallisepticum Vaccine Efficacy
MG vaccine efficacy is measured by reduction in clinical signs, air sac lesion scores, egg production losses, and MG isolation rates. Live vaccines provide superior protection against respiratory disease compared to bacterins. However, live vaccines do not prevent infection; they reduce shedding and clinical severity. Bacterins reduce egg transmission but do not eliminate infection. Efficacy is influenced by:
- Vaccine strain virulence and route.
- Timing of vaccination relative to field exposure.
- Presence of concurrent respiratory pathogens (e.g., infectious bronchitis virus, Newcastle disease virus, Avian Influenza (H5N1)).
- Flock health and nutritional status.
Differential Diagnosis from Other Respiratory Pathogens
Respiratory disease in poultry has multiple etiologies. Clinical signs alone are insufficient for diagnosis. The following table summarizes key differentials for fowl pox and MG.
| Pathogen | Key Clinical Features | Diagnostic Methods | | :-, | :-, | :-, | | Fowl Pox Virus | Cutaneous nodules on comb/wattles; diphtheritic plaques in mouth/trachea; inclusion bodies on histopathology | Histopathology (Bollinger bodies); virus isolation in embryonated eggs or cell culture; PCR; electron microscopy | | Mycoplasma gallisepticum | Chronic respiratory disease; sinusitis (turkeys); rales; conjunctivitis; airsacculitis; egg drop | Serology (ELISA, serum plate agglutination); PCR; culture on Frey's medium; DNA sequencing | | Infectious Bronchitis Virus | Acute respiratory distress; nephritis (some strains); egg shell abnormalities | RT-PCR; virus isolation; serology (ELISA, HI) | | Newcastle Disease Virus | Respiratory, nervous, and enteric signs; high mortality (velogenic strains) | RT-PCR; virus isolation; serology (HI) | | Avian Influenza Virus | Respiratory signs; cyanosis; edema; sudden death; egg drop | RT-PCR; virus isolation; serology (AGID, ELISA) | | Infectious Coryza (see Infectious Coryza in Poultry and Ducks) | Facial edema; nasal discharge; conjunctivitis; swollen sinuses | Culture (Haemophilus paragallinarum); PCR; serology | | Avian Cholera (see Fowl Cholera in Poultry) | Acute septicemia; cyanosis; diarrhea; sudden death | Culture (Pasteurella multocida); PCR; serology | | Escherichia coli (see Escherichia coli in Chickens and Poultry Products) | Airsacculitis; pericarditis; perihepatitis; colisepticemia | Culture; PCR; serotyping |
Diagnostic Workflow
The following Mermaid diagram illustrates a diagnostic decision tree for respiratory disease in poultry, incorporating fowl pox and MG.
flowchart TD
A[Clinical Signs: Respiratory distress, lesions, egg drop], > B{Physical Exam}
B, > C[Cutaneous nodules or oral plaques?]
C, >|Yes| D[Suspect Fowl Pox]
D, > E[Histopathology / PCR]
E, > F[Confirm Fowl Pox]
C, >|No| G[Nasal discharge, sinusitis, rales?]
G, > H[Suspect Bacterial or Viral Respiratory Infection]
H, > I[Collect samples: swabs, serum, tissues]
I, > J{Serology / PCR}
J, > K[MG positive?]
K, >|Yes| L[Confirm Mycoplasma gallisepticum]
K, >|No| M[Test for other pathogens: IBV, NDV, AIV, IC, FC]
M, > N[PCR / Culture / Sequencing]
N, > O[Identify causative agent]
L, > P[Consider MG vaccination history]
F, > Q[Consider fowl pox vaccination history]
P, > R[Implement control measures]
Q, > R
R, > S[Biosecurity, vaccination, treatment]
Vaccination Strategies in Flocks
Fowl Pox Vaccination
- Broilers: Vaccination is uncommon due to short lifespan. Vaccination may be considered in high-risk areas or for longer-lived breeds (e.g., roasters).
- Layers and Breeders: Vaccination is routine. Primary vaccination at 8 to 12 weeks of age via wing web stab. A booster may be given at 16 to 20 weeks.
- Turkeys: Vaccination is recommended in endemic areas. Pigeon pox vaccine is often used due to lower virulence.
Mycoplasma Gallisepticum Vaccination
- Commercial Layers: Live vaccines (ts-11 or 6/85) are commonly used. Vaccination is performed at 6 to 10 weeks of age via eye drop or spray.
- Breeders: Inactivated bacterins are used in breeders to reduce egg transmission. Priming with a live vaccine followed by a killed booster is a common protocol.
- Turkeys: Live F strain vaccine is used with caution due to residual virulence. ts-11 is preferred in turkeys.
Safety and Adverse Events
Fowl Pox Vaccines
- Generalized Pox: Can occur in immunocompromised birds or if vaccine is administered to very young chicks (under 4 weeks).
- Vaccine Reaction: Swelling at the wing web site is expected. Severe reactions may indicate bacterial contamination or improper technique.
- Reversion to Virulence: Live fowl pox vaccines are considered stable, but reversion has been reported with some strains.
Mycoplasma Gallisepticum Vaccines
- Vaccine Reaction: Mild respiratory signs may occur 1 to 2 weeks post-vaccination with live vaccines. Severe reactions suggest concurrent infection or improper administration.
- Shedding: Live MG vaccines can shed to unvaccinated birds. The F strain has higher shedding potential than ts-11 or 6/85.
- Residual Virulence: The F strain can cause disease in turkeys and should not be used in turkey flocks.
Conclusion
Vaccination against fowl pox and Mycoplasma gallisepticum is a critical component of poultry health management. Fowl pox vaccines are predominantly live attenuated and administered via wing web stab, with efficacy assessed by vaccine take. MG vaccines include live attenuated strains (F, ts-11, 6/85) and inactivated bacterins, with administration routes tailored to the vaccine type. Differential diagnosis from other respiratory pathogens is essential for appropriate vaccine selection and outbreak management. A comprehensive approach combining vaccination, biosecurity, and diagnostic surveillance remains the most effective strategy for controlling these economically important diseases.
References
- Swayne, D.E., Glisson, J.R., McDougald, L.R., Nolan, L.K., Suarez, D.L., and Nair, V. (Eds.). Diseases of Poultry. 14th Edition. Wiley-Blackwell.
- Ley, D.H. Mycoplasma gallisepticum infection. In: Swayne, D.E., et al., Eds. Diseases of Poultry. 14th Edition. Wiley-Blackwell.
- Tripathy, D.N., and Reed, W.M. Pox. In: Swayne, D.E., et al., Eds. Diseases of Poultry. 14th Edition. Wiley-Blackwell.
- Kleven, S.H. Mycoplasma gallisepticum vaccination: current status and future directions. World's Poultry Science Journal.
- Whithear, K.G. Control of avian mycoplasmoses by vaccination. Revue Scientifique et Technique (International Office of Epizootics).